Patients must not have clinical evidence of central nervous system involvement by lymphoma; if performed, any laboratory or radiographic tests performed to assess central nervous system (CNS) involvement must be negative
Patient does not have any documented history of central nervous system (CNS) involvement by mantle cell lymphoma; this includes no evidence of parenchymal brain, spinal cord, or cerebrospinal fluid involvement; radiculopathy symptoms from nerve root compression by lymphoma do not constitute CNS involvement
Presence of central nervous system (CNS) involvement requiring active treatment
Symptomatic or progressing or steroid requiring Central Nervous System (CNS) involvement disease at least four weeks prior to randomization
Known central nervous system (CNS) involvement
Patients with a known central nervous system (CNS) involvement of lymphoma are not eligible (CNS staging not required)
Leukemia with active central nervous system (CNS) involvement
Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy
Subjects with known active or history of CNS involvement by malignancy
Known central nervous system involvement by PTCL
Active central nervous system (CNS) involvement by leukemia
Current or past history of central nervous system (CNS) disease, or CNS involvement by MM
Known active central nervous system (CNS) involvement by lymphoma, including parenchymal and/or lymphomatous meningitis
Known CNS involvement at diagnosis
Patients with evidence of current central nervous system leukemic involvement
Symptomatic central nervous system (CNS) involvement which are neurologically unstable or requiring increasing doses of steroids to control.
Central nervous system involvement
Presence of active/uncontrolled central nervous system involvement
Central nervous system (CNS) involvement
Patients with any central nervous system involvement or CTCL.
Central nervous system involvement
Patients with known central nervous system (CNS) involvement of lymphoma are not eligible
Evidence of leukemic meningitis or other central nervous system (CNS) involvement by leukemia
Active, uncontrolled central nervous system (CNS) involvement by lymphoma
Active involvement of the central nervous system (CNS) by lymphoma; work-up for CNS involvement at diagnosis will be directed as per the treating physician and will depend on specific clinical circumstances (no brain imaging or lumbar puncture is required by this protocol)
Clinical evidence suggestive of central nervous system (CNS) involvement with MDS unless a lumbar puncture confirms the absence of leukemic blasts in the cerebrospinal fluid (CSF)
Patients must not have known central nervous system (CNS) involvement of lymphoma
Central nervous system (CNS) lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells
Patients with metabolic storage diseases who have severe central nervous system (CNS) involvement of disease, defined as intelligence quotient (IQ) score < 70
Patients with known active central nervous system (CNS) involvement by lymphoma, including leptomeningeal involvement
Subject has confirmed central nervous system (CNS) involvement by DLBCL. Subjects at risk for CNS involvement per Investigator assessment must receive prophylaxis. For subjects at risk, or with any neurological symptoms, testing for CNS involvement is required at Screening.
Has clinical signs of central nervous system (CNS) involvement of MM.
Active CNS involvement
Known active central nervous system (CNS) involvement by lymphoma should be excluded from this clinical trial
Central nervous system involvement by lymphoma, including leptomeningeal involvement
Central Nervous System (CNS) involvement with multiple myeloma defined as csf positivity for plasma cells or a parenchymal CNS plasmacytoma
EXCLUSION - INFUSION: Patients with central nervous system involvement
Known central nervous system (CNS) involvement by lymphoma
Myeloma-related central nervous system involvement
Central nervous system involvement
Active central nervous system (CNS) involvement with leukemia
Active CNS involvement of their malignancy.
Central nervous system involvement with lymphoma at any time in the patient’s history; intrathecal prophylaxis during induction is allowed as long as active disease has not been identified
Active central nervous system (CNS) involvement by malignancy, except in cases of virus-associated malignancies with CNS involvement in which case the patient may benefit from the transplant to control the malignancy
Suggestive central nervous system involvement with leukemia
Central nervous system involvement
CNS metastatic involvement
Symptomatic central nervous system involvement.
Active central nervous system (CNS) lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells that requires therapy
Central nervous system (CNS) involvement by lymphoma/leukemia
Central nervous system involvement.
Known central nervous system or meningeal involvement (in the absence of symptoms investigation into central nervous system involvement is not required)
Patients with active known central nervous system (CNS) involvement of CLL or lymphoma; (patients with history of CNS CLL or lymphoma now in remission are eligible for the trial)
Known central nervous system (CNS) involvement by malignancy
Patients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy and/or standard cranial-spinal radiation
Known central nervous system (CNS) involvement by lymphoma; patients at high risk for secondary CNS involvement but without neurologic symptoms suspected to be due to lymphoma are allowed to be enrolled and receive intrathecal chemotherapy including but not limited to methotrexate, cytarabine and glucocorticoids; patients who are enrolled and subsequently identified to have pathologic confirmation of CNS involvement by lymphoma may be continued on study at the discretion of the principal investigator
Any active central nervous system or meningeal involvement
Known central nervous system (CNS) involvement with CLL or T-LGL
Evidence of lymphoma outside of the central nervous system\r\n* Ocular involvement will not exclude
Known central nervous system involvement
Known, current central nervous system disease involvement or untreated brain metastases
Active, uncontrolled central nervous system (CNS) leukemia involvement
Known clinically active central nervous system (CNS) involvement; prior evidence of CNS involvement successfully treated with surgery or radiation therapy will not be exclusion for participation as long as they are deemed under control at the time of study enrollment and there are no neurological signs of potential CNS involvement
History or presence of clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis, active central nervous system MM involvement and/or carcinomatous meningitis; subjects with previously treated central nervous systems involvement may participate, provided they are free of disease in the CNS (documented by flow cytometry performed on the cerebrospinal fluid [CSF] within one week of enrollment) and have no evidence of new sites of CNS activity
Known clinically active CNS involvement.
Subject has known active central nervous system (CNS) involvement from AML
Active central nervous system (CNS) involvement by lymphoma, including untreated symptomatic epidural disease
Known active involvement of the central nervous system by lymphoma or leukemia
Active central nervous system or meningeal involvement by lymphoma. Subjects with untreated brain metastases/central nervous system (CNS) disease will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with a history of CNS or meningeal involvement must be in a documented remission by cerebrospinal fluid (CSF) evaluation and contrast-enhanced magnetic resonance imaging (MRI) imaging for at least 90 days prior to registration.
Prior central nervous system (CNS) involvement by tumor cells;
Patients with active central nervous system (CNS) involvement with lymphoma are not eligible
Documented history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. If either is suspected, whole body magnetic resonance imaging (MRI) and lumbar cytology are required
Known central nervous system (CNS) involvement
Participant has known active central nervous system (CNS) involvement with AML.
Patients with known active central nervous system (CNS) disease, including leptomeningeal involvement
Active central nervous system (CNS) involvement by malignancy
Patients with history of central nervous system (CNS) involvement
Active central nervous system (CNS) metastases and/or leptomeningeal involvement
History or presence of clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis, active central nervous system MM involvement and/or carcinomatous meningitis; subjects with previously treated central nervous systems involvement may participate, provided they are free of disease in the CNS (documented by flow cytometry performed on the cerebrospinal fluid (CSF) within one week of enrollment) and have no evidence of new sites of CNS activity
Known central nervous system (CNS) involvement
Active central nervous system (CNS) involvement of leukemia (lumbar puncture not required to rule out CNS involvement if not suspected)
Subjects are not eligible if there is a prior history or current evidence of central nervous system or leptomeningeal involvement
Known active central nervous system (CNS) involvement
Has either clinical evidence of or history of central nervous system involvement by AML.
Known active central nervous system (CNS) involvement by MM
The toxicity profile of nivolumab in patients with disease involvement of the central nervous system (CNS) is unknown
Subject has known active central nervous system (CNS) involvement with AML
Active or previous central nervous system leukemia involvement
Central nervous system involvement with disease under study (myeloma), or concurrent AL amyloidosis or plasma cell leukemia
Patients who have known central nervous system involvement with multiple myeloma will be excluded from this clinical trial
Known central nervous system (CNS) involvement by lymphoma
Evidence of active central nervous system (CNS) involvement
Active or previous central nervous system leukemia involvement
known active central nervous system (CNS) involvement by malignancy.
Central nervous system involvement with MM (by clinical symptoms and signs).
Central nervous system (CNS) involvement, including lymphomatous meningitis
Active central nervous system (CNS) or testicular involvement by leukemia
Has known active central nervous system (CNS) involvement by lymphoma, including leptomeningeal involvement; subjects with prior CNS involvement by lymphoma must have remission of the CNS component of the lymphoma; these subjects must have a baseline magnetic resonance imaging (MRI) during screening without evidence of new or enlarging brain lesions and must not have any new or progressive neurologic symptoms
Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma
Prior central nervous system (CNS) involvement by tumor cells
No active central nervous system (CNS) metastatic disease. NOTE: Subjects with CNS involvement must meet ALL of the following to be eligible:
History of or known active central nervous system (CNS) involvement with AML
Active central nervous system (CNS) involvement or leptomeningeal involvement
Prior or active central nervous system (CNS) involvement by myeloma (eg leptomeningeal disease); screening for this, for example, by lumbar puncture, is only required if suspicious symptoms or radiographic findings are present
Participant has known Central Nervous System (CNS) involvement with AML.
A history of AML related central nervous system (CNS) involvement is allowed if most recent cerebrospinal fluid (CSF) analysis is negative at least 2 weeks prior to study treatment
Patients with current central nervous system (CNS) involvement by malignancy (either by imaging or cerebrospinal fluid involvement or biopsy-proven)
Patients with known active central nervous system (CNS) disease, including leptomeningeal involvement
Active involvement of the central nervous system with malignancy
History of plasma cell leukemia or multiple myeloma (MM) central nervous system (CNS) involvement
Active, untreated central nervous system (CNS) involvement
No known history or suspicion of central nervous system involvement by lymphoma
Participants with central nervous system (CNS) lymphoma (primary or secondary involvement), primary effusion DLBCL, and primary cutaneous DLBCL
Active central nervous system (CNS)-only involvement by malignancy (note: participants with secondary CNS involvement are allowed on study)
Absence of active central nervous system (CNS) involvement; NOTE: pre-enrollment lumbar puncture not mandatory
Known central nervous system (CNS) involvement
Patients with active central nervous system (CNS) involvement with lymphoma are not eligible
Subjects must not have known central nervous system involvement by disease (parenchymal, meningeal or cerebrospinal fluid)
Known cytopathologically confirmed central nervous system (CNS) infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required)
Central nervous system metastases, including leptomeningeal involvement
Central nervous system (CNS) involvement
Uncontrolled central nervous system (CNS) involvement by tumor cells within the past 2 months
Central nervous system (CNS) involvement by lymphoma
CNS involvement with malignancy.
Known central nervous system involvement with the disease under study
Primary central nervous system involvement only
Patients with known central nervous system involvement should be excluded from this clinical trial
Central nervous system (CNS) or meningeal involvement, or cord compression by the lymphoma; history of CNS lymphoma
Have prior or active central nervous system (CNS) involvement (e.g. leptomeningeal disease, parenchymal masses) with myeloma; screening for this (e.g. with lumbar puncture) is not required unless suspicious symptoms are present
Central nervous system (CNS) involvement
History of or active central nervous system (CNS) or peripheral nerve stimulation (PNS) involvement
Has known active central nervous system involvement of the malignancy.
Central nervous system (CNS) involvement by lymphoma (clinically or cytologically confirmed)
Patients with current central nervous system (CNS) involvement by malignancy (either by imaging or cerebrospinal fluid involvement or biopsy-proven)
Patients with known or suspected central nervous system involvement of lymphoma.
All patients with central nervous system involvement with lymphoma
Known lymphomatous involvement of the central nervous system
History of central nervous system multiple myeloma involvement
Patients with known central nervous system (CNS) involvement
Known brain metastases or central nervous system (CNS) involvement
Suspected AML-related central nervous system involvement; a lumbar puncture (LP) is not required to exclude central nervous system (CNS) disease
Subjects with known central nervous system involvement with multiple myeloma
Active involvement of the central nervous system with malignancy
Subjects must not have prior or active central nervous system (CNS) involvement (e.g. leptomeningeal disease, parenchymal masses) with myeloma; screening for this (e.g. with lumbar puncture) is not required unless suspicious symptoms are present
Has known clinically active central nervous system (CNS) involvement
Known central nervous system (CNS) tumor involvement
History of plasma cell leukemia or MM central nervous system (CNS) involvement
History of CNS involvement by MM
Active central nervous system (CNS) involvement within the previous 2 months
Active central nervous system (CNS) involvement of the underlying malignancy
Known evidence of active cerebral/meningeal CLL; patients may have history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease at the time of registration
Known active central nervous system involvement
Central nervous system (CNS) involvement
Central nervous system involvement of the disease under study
Central nervous system involvement
Known lymphomatous involvement of the central nervous system
Known central nervous system involvement
Presence of central nervous system involvement of leukemia or a history of primary central nervous system leukemia.
Active central nervous system (CNS) neoplastic involvement
Patients with history of extramedullary AML, except for central nervous system (CNS) involvement that is currently controlled, will not be eligible for enrollment
Patients must not have active central nervous system involvement
Primary central nervous system lymphoma or known intracranial involvement
Central nervous system (CNS) involvement within 3 months
Patient must have no current or prior history of central nervous system (CNS) involvement
Skin involvement.
Active involvement of the central nervous system with malignancy; this can be documented as a normal neurological exam and/or a negative cerebrospinal fluid (CSF) analysis
Subjects are not eligible if there is a prior history or current evidence of central nervous system or leptomeningeal involvement
Known active central nervous system (CNS) involvement
No evidence of extramedullary leukemia, such as central nervous system (CNS) or soft tissue involvement
Patient with active central nervous system (CNS) involvement
Participants with known central nervous system (CNS) involvement with leukemia or who are receiving intrathecal chemotherapy that is either prophylactic or therapeutic; history of CNS involvement that has been completely treated (no longer receiving intrathecal chemotherapy) will be allowed
Known central nervous system or meningeal involvement (in the absence of symptoms, investigation into central nervous system involvement is not required)
Patients with known central nervous system (CNS) involvement
Central nervous system or meningeal involvement
Active involvement of the central nervous system with malignancy
Active involvement of the central nervous system with malignancy
Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy
Central nervous system (CNS) leukemic involvement not clearing with intrathecal chemotherapy and/or cranial radiation prior to initiation of conditioning (day -6)
Patients with known central nervous system (CNS) involvement by leukemia
Known leptomeningeal involvement.
Central nervous system involvement.
Patients with active central nervous system (CNS) involvement by malignant cells
Has active central nervous system (CNS) involvement (documented by radiologic lesions and/or malignant cells in the cerebrospinal fluid [CSF]).
History of or known active central nervous system (CNS) involvement or leptomeningeal involvement
Subjects with central nervous system (CNS)-only involvement by malignancy (note: subjects with secondary CNS involvement are allowed on study)
Active central nervous system involvement with AML.
Has central nervous system (CNS) involvement of leukemia or a history of CNS leukemia
Known central nervous system or meningeal involvement (in the absence of symptoms, investigation into central nervous system involvement is not required)
Known active involvement of the central nervous system by lymphoma or leukemia
Known central nervous system involvement by multiple myeloma
History of plasma cell leukemia or central nervous system (CNS) involvement
Patients with known central nervous system involvement should be excluded from this clinical trial
Central nervous system involvement (Bing-Neel syndrome)
Known involvement of central nervous system
Central nervous system (CNS) leukemic involvement not clearing with intrathecal chemotherapy; diagnostic lumbar puncture is to be performed
Central nervous system involvement by lymphoma, including leptomeningeal involvement
Active central nervous system (CNS) disease – if a history of AML related CNS involvement, screening cerebrospinal fluid (CSF) analysis must be negative
Patient has a known or suspected primary central nervous system (CNS) tumor or CNS tumor involvement or active leptomeningeal disease.
Known central nervous system (CNS) involvement with lymphoma.
Active central nervous system (CNS) lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells that requires therapy
Patient has distant metastatic disease, including central nervous system (CNS) tumor involvement
Clinical evidence of central nervous system involvement.
Patients with central nervous system (CNS) involvement unless they meet ALL of the following criteria:
Symptomatic central nervous system (CNS) involvement by AML
Untreated central nervous system (CNS) involvement
Known central nervous system involvement or brain metastases
Active central nervous system (CNS) involvement or leptomeningeal metastases involvement
Known active central nervous system (CNS) involvement with AML at study entry
Active central nervous system involvement by leukemia
Patients with suspected central nervous system (CNS) involvement should undergo lumbar puncture; those with documented CNS involvement will be excluded
Active central nervous system involvement
Uncontrolled central nervous system (CNS) disease involvement
Patients with a history of central nervous system involvement by CLL or who have prolymphocytic leukemia (PLL)
AML central nervous system (CNS) involvement
Patients with documented central nervous system involvement of AML
Has known clinically active central nervous system (CNS) involvement OR history of resolved CNS involvement by multiple myeloma
Active central nervous system involvement by malignancy
Central nervous system involvement; a lumbar puncture does not need to be performed unless there is clinical suspicion of leptomeningeal disease
With central nervous system (CNS) leukemic involvement not clearing with intrathecal chemotherapy, cranial irradiation or both prior to initiating conditioning (day -6)
Documented current central nervous system involvement by multiple myeloma
Patients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy
Patients with history of central nervous system (CNS) involvement or active CNS involvement by malignancy
Patients must have no known central nervous system (CNS) involvement by lymphoma
Central nervous system (CNS) involvement by lymphoma including parenchymal brain or spinal cord lymphoma or known presence of leptomeningeal disease prior to registration
Patients with metabolic storage diseases who have severe central nervous system (CNS) involvement of disease, defined as intelligence quotient (IQ) score < 70
Active central nervous system (CNS) involvement by malignancy
Exhibiting clinical signs of or has a known history of meningeal or central nervous system involvement by multiple myeloma
History of or current, central nervous system involvement with AML.
Patients must not have clinical evidence of central nervous system (CNS) involvement by lymphoma            \r\n* Any laboratory or radiographic tests performed to assess CNS involvement must be negative and must be performed within 42 days prior to registration
Known clinically active central nervous system involvement.
Subject has known active central nervous system involvement with AML.
Active Central Nervous System (CNS) involvement by malignancy
Has known clinically active central nervous system (CNS) involvement
Have active leukemic involvement of the central nervous system (CNS).
Central nervous system (CNS) involvement by lymphoma/leukemia
Patients with controlled asymptomatic central nervous system involvement are allowed.
Patients who have symptomatic central nervous system (CNS) involvement are not eligible
Central nervous system involvement with lymphoma, including parenchymal and leptomeningeal disease
Active central nervous system (CNS) involvement of disease
CNS lymphoma involvement
Patients must not have active involvement of the central nervous system (CNS) with MM (by clinical evaluation); patients with documentation of, or clinical signs or symptoms consistent with, CNS involvement of MM must have a lumbar puncture that is negative for CNS involvement of MM; the lumbar puncture must be completed within 14 days prior to registration; patients with no previous history of documented CNS involvement and with no clinical signs or symptoms consistent with CNS involvement are not required to have completed a lumbar puncture prior to registration; note that monitoring of CNS involvement and treatment with intrathecal therapy is recommended during protocol treatment
Active AML involvement of the central nervous system (CNS) with disease refractory to intrathecal chemotherapy
Central nervous system (CNS) involvement.
Patients with documented central nervous system (CNS) involvement
Subject who has central nervous system (CNS) or meningeal involvement by lymphoma.
Subjects with Central Nervous System involvement with multiple myeloma
Central nervous system involvement of the CLL
Active uncontrolled central nervous system involvement
Presence or history of central nervous system involvement by lymphoma.
Patient must have no known central nervous system (CNS) involvement
Patients with known central nervous system involvement at the time of study entry will be excluded from this clinical trial
AML patients with known, active leptomeningeal/central nervous system (CNS) involvement
Known, current central nervous system disease involvement or untreated brain metastases
Participants with active central nervous system (CNS) involvement are excluded; patients with suspected CNS disease should be worked up appropriately prior to enrollment
No active extramedullary leukemia or known active central nervous system (CNS) involvement by malignancy; such disease treated into remission is permitted
Primary or secondary Central Nervous System involvement by lymphoma.
Myeloma-related central nervous system involvement
Known central nervous system (CNS) involvement by malignancy
Patients with leukemic involvement of the central nervous system
Patient has active or history of central nervous system (CNS) disease or meningeal involvement
Central nervous system involvement (based on clinical assessment)
Known central nervous system (CNS) involvement
Symptomatic central nervous system (CNS) lymphoma involvement
Known evidence of active cerebral/meningeal CLL; patients may have history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease at the time of registration
Known clinically active central nervous system involvement
Known active involvement of the central nervous system by lymphoma or leukemia
Active central nervous system (CNS) involvement with leukemia
Central nervous system involvement
Known lymphomatous involvement of the central nervous system.
Known central nervous system or meningeal involvement (in the absence of symptoms investigation into central nervous system involvement is not required)
Participant has known active central nervous system (CNS) involvement with AML.
Active central nervous system involvement by lymphoma
Known central nervous system involvement
Central nervous system involvement.
Known involvement of the central nervous system by WM.
Subjects with known or suspected central nervous system (CNS) involvement are not eligible
Patients with known central nervous system (CNS) involvement are excluded from this clinical trial
Central nervous system (CNS) involvement by CLL.
Any past or current Central Nervous System (CNS) involvement, including leptomeningeal leukemia.
Central nervous system involvement
Research participants with known brain metastases (central nervous system [CNS] involvement either parenchymal or leptomeningeal involvement)
Patients with a history of central nervous system involvement by lymphoma
Has evidence of uncontrolled central nervous system (CNS) involvement (previous radiation and off steroids is acceptable)
Central nervous system (CNS) involvement by lymphoma
Phase II: Patients with untreated, relapsed or refractory T-cell lymphoma, including patients with central nervous system (CNS) involvement or lymphomatous meningitis are allowed on study
Active involvement of the central nervous system with malignancy
History of central nervous system (CNS) involvement by myeloma
Known central nervous system (CNS) involvement of lymphoma
Known central nervous system (CNS) involvement
Central nervous system (CNS) involvement of the patient's lymphoma
Patients with active central nervous system (CNS) involvement with lymphoma should be excluded from this clinical trial
Presence of confirmed distant metastases, including central nervous system and vertebral or meningeal involvement
Central nervous system disease involvement
Patients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy and/or standard cranial-spinal radiation
Central nervous system involvement
Patients with a history of central nervous system (CNS) leukemia are eligible if they are not symptomatic from current CNS involvement\r\n* If there is CNS involvement that is known prior to enrollment or identified subsequently, it will be treated accordingly
Known Central nervous system involvement, brain metastasis
Known central nervous system or meningeal involvement (in the absence of symptoms investigation into central nervous system involvement is not required); patients with human T-cell lymphotropic virus type 1 (HTLV1) adult T-cell leukemia/lymphoma (ATLL) and controlled central nervous system (CNS) or meningeal involvement may be enrolled after discussion with the Memorial Sloan Kettering (MSK) principal investigator
Patients with central nervous system (CNS) involvement
Known active central nervous system involvement
Central nervous system (CNS) leukemic involvement not clearing with intrathecal chemotherapy and/or cranial radiation prior to initiation of conditioning; diagnostic lumbar puncture is to be performed per protocol
Untreated central nervous system (CNS) involvement; (treated CNS involvement is permitted only if the patient is not currently on steroid therapy or has remained on a stable, unchanged dose of steroid for >= 2 weeks)
Histolo-cytologically proven PMLBL (phase II)\r\n* PMLBL without central nervous system (CNS) involvement\r\n* Slides will be reviewed by the national pathology panel, but review is not mandatory before registration
Known central nervous system (CNS) involvement
Central nervous system involvement.
Active central nervous system or meningeal involvement by lymphoma; patients with a history of central nervous system (CNS) or meningeal involvement must be in a documented remission by cerebrospinal fluid (CSF) evaluation and contrast magnetic resonance imaging (MRI) for at least 3 months prior to study entry
Patient with active central nervous system (CNS) involvement with lymphoid malignancy
Presence or history of central nervous system involvement by lymphoma
Known central nervous system (CNS) involvement by lymphoma.
Known central nervous system involvement by leukemia
Known cytopathologically confirmed central nervous system (CNS) infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required)
Patients with central nervous system involvement by APL are eligible and may receive concomitant treatment with radiation therapy and/or intrathecal chemotherapy in accordance with standard medical practice
Uncontrolled central nervous system (CNS) involvement with disease
Known active CNS involvement
Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy
No known central nervous system involvement by myeloma.
Known central nervous system (CNS) lymphoma involvement
Evidence of AML central nervous system (CNS) involvement
Disease-related central nervous system involvement
Known CNS involvement of indolent lymphoma
Documented current central nervous system involvement by leukemia or lymphoma
Central nervous system (CNS) involvement.
Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy
CLL central nervous system involvement
Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy and/or standard cranial-spinal radiotherapy
No known involvement of central nervous system by lymphoma
Active diagnosis of central nervous system (CNS) involvement with CLL
Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy
Evidence of sanctuary site involvement by disease, e.g., central nervous system, ocular, testicular involvement
Active central nervous system (CNS) involvement by malignancy (defined as CNS-3 per National Comprehensive Cancer Network [NCCN] guidelines)
Patient has central nervous system metastatic involvement. Patients with previously treated CNS metastases are also excluded.
Known central nervous system lymphoma or ALL with central nervous system (CNS) involvement
Central nervous system (CNS) involvement of DLBCL
Active involvement of the central nervous system with malignancy
Current central nervous system (CNS) involvement by lymphoma
Untreated central nervous system involvement
Known central nervous system (CNS) involvement
CNS or leptomeningeal involvement of lymphoma
Active central nervous system (CNS) disease involvement
Known central nervous system involvement
Clinically active central nervous system (CNS) cancer involvement. Imaging to exclude CNS involvement not required.
Known central nervous system involvement
Active central nervous system involvement by malignancy; central nervous system disease that has been treated into remission is permitted; a chart note of the clinician’s impression of lack of central nervous system (CNS) involvement is acceptable
Known active and uncontrolled central nervous system (CNS) involvement of leukemia (a lumbar puncture does not need to be performed as a part of screening)
Symptomatic central nervous system (CNS) involvement
Known active cerebral/meningeal involvement with lymphoma; asymptomatic patients with previously treated and resolved central nervous system (CNS) lymphoma involvement are permitted
Patients with untreated central nervous system involvement by AML should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events; this is an uncommon situation in AML and therefore a lumbar puncture for cerebrospinal fluid (CSF) sampling or magnetic resonance imaging (MRI) imaging are NOT necessary to rule out central nervous system (CNS) involvement in the absence of clinical suspicion by the treating physician
Patients must have relapsed or refractory cluster of differentiation (CD) 20+ lymphoid malignancies with either documented central nervous system (CNS) involvement or peripheral nerve infiltration
Had evidence of active central nervous system (CNS) involvement
Active central nervous system (CNS) lymphoma/leukemia - Patients with prior CNS involvement are eligible provided that it has been treated and is in remission
Documented current central nervous system involvement
Symptomatic central nervous system involvement
Symptomatic central nervous system (CNS) involvement
Known uncontrolled central nervous system involvement
Lymphoma involvement of the central nervous system
Active or symptomatic central nervous system (CNS) disease or epidural involvement
For Part B only: Known leukemic involvement or clinical symptoms of leukemic involvement of the central nervous system
Evidence of active cerebral/meningeal disease; patients may have history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease at the time of registration
Symptomatic, steroid-requiring or progressive central nervous system (CNS) involvement
Active involvement of the Central Nervous System (CNS).
Clinically uncontrolled central nervous system (CNS) involvement
Central nervous system involvement
Patients with central nervous system (CNS) metastatic involvement.
Clinically uncontrolled central nervous system (CNS) involvement
Patients with a history of central nervous system involvement by lymphoma
Patients with known central nervous system involvement.
Patients must not have clinical evidence of central nervous system involvement by lymphoma, since proposed treatment would not be able to address it adequately; any laboratory (e.g., lactate dehydrogenase [LDH]) or radiographic tests performed to access central nervous system (CNS) involvement must be negative and must be performed within 42 days prior to registration
Clinical evidence of CNS involvement by lymphoma
Known, active (symptomatic) involvement of the central nervous system by leukemia.
Known central nervous system (CNS) involvement
Active central nervous system (CNS) involvement of their malignancy.
Known leukemic involvement of the central nervous system.
Documented current central nervous system involvement by leukemia or lymphoma
Central nervous system involvement
No active extramedullary leukemia or known active central nervous system (CNS) involvement by malignancy; such disease treated into remission is permitted
Has central nervous system involvement
Central nervous system (CNS) lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells
Known Central Nervous System (CNS) involvement by lymphoma.
Presence of central nervous system (CNS) involvement with Hodgkin lymphoma
Uncontrolled central nervous system (CNS) involvement by tumor cells
Active central nervous system (CNS) involvement by malignancy
Central nervous system (CNS) lymphomatous involvement or leptomeningeal lymphoma
Prior central nervous system (CNS) involvement by tumor is permissible if previously treated and clinically stable for two weeks after completion of treatment.
History of central nervous system involvement of lymphoma;
All patients with active central nervous system involvement with lymphoma
Known evidence of active cerebral/meningeal CLL; patients may have history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease at the time of registration
History of central nervous system (CNS) involvement
Active central nervous system (CNS) lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells that requires therapy
Known presence of central nervous system (CNS) involvement by lymphoma
Known central nervous system (CNS) involvement
No active extramedullary leukemia or known active central nervous system (CNS) involvement by malignancy; such disease treated into remission is permitted
Patients with known central nervous system (CNS) involvement
Participants with known central nervous system (CNS) involvement of lymphoma
Patient must not have active central nervous system (CNS) involvement
INCLUSION CRITERIA FOR PATIENTS: No central nervous system involvement of disease
Active central nervous system (CNS) involvement by malignant cells
EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Active involvement of the central nervous system with malignancy (previous central nervous system [CNS] involvement is allowed if clearance of CNS disease has been documented prior to enrollment)
Active central nervous system (CNS) involvement by malignant cells
Patients with active central nervous system involvement
Symptomatic central nervous system involvement.
History of central nervous system involvement or symptoms suggestive of central nervous system involvement by multiple myeloma
Known central nervous system involvement by multiple myeloma
Active central nervous system (CNS) involvement by malignant cells
Active central nervous system (CNS) involvement by malignant cells
Clinical suspicion of active central nervous system (CNS) involvement by leukemia
Known central nervous system (CNS) involvement
Known central nervous system (CNS) involvement by AML
Has presence of central nervous system (CNS) involvement of leukemia or a history of CNS leukemia
Patients must not have known central nervous system (CNS) involvement
Patients with known central nervous system (CNS) involvement
Known central nervous system (CNS) involvement of lymphoma (CNS staging not required)
Clinical signs of central nervous system (CNS) involvement of MM.
Known uncontrolled central nervous system involvement by malignant disease
